NO20090986L - Sammensmeltet heterosyklisk derivat og anvendelse derav - Google Patents
Sammensmeltet heterosyklisk derivat og anvendelse deravInfo
- Publication number
- NO20090986L NO20090986L NO20090986A NO20090986A NO20090986L NO 20090986 L NO20090986 L NO 20090986L NO 20090986 A NO20090986 A NO 20090986A NO 20090986 A NO20090986 A NO 20090986A NO 20090986 L NO20090986 L NO 20090986L
- Authority
- NO
- Norway
- Prior art keywords
- heterocyclic derivative
- cancer
- inhibitor
- merged
- compound
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 abstract 1
- 101100342473 Drosophila melanogaster Raf gene Proteins 0.000 abstract 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 abstract 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 1
- 101100523543 Rattus norvegicus Raf1 gene Proteins 0.000 abstract 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 abstract 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 abstract 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 101100523549 Xenopus laevis raf1 gene Proteins 0.000 abstract 1
- 101150037250 Zhx2 gene Proteins 0.000 abstract 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 abstract 1
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003966 growth inhibitor Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006213981 | 2006-08-04 | ||
| JP2006331230 | 2006-12-07 | ||
| JP2007144072 | 2007-05-30 | ||
| PCT/JP2007/065681 WO2008016192A2 (en) | 2006-08-04 | 2007-08-03 | Fused heterocyclic derivative and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20090986L true NO20090986L (no) | 2009-05-04 |
Family
ID=38996616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090986A NO20090986L (no) | 2006-08-04 | 2009-03-04 | Sammensmeltet heterosyklisk derivat og anvendelse derav |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8044049B2 (zh) |
| EP (1) | EP2049541B1 (zh) |
| JP (1) | JP5238697B2 (zh) |
| KR (1) | KR20090047509A (zh) |
| AR (1) | AR062207A1 (zh) |
| AU (1) | AU2007279595A1 (zh) |
| BR (1) | BRPI0714665A2 (zh) |
| CA (1) | CA2659971A1 (zh) |
| CL (1) | CL2007002261A1 (zh) |
| CO (1) | CO6150183A2 (zh) |
| CR (1) | CR10607A (zh) |
| IL (1) | IL196799A0 (zh) |
| MA (1) | MA30651B1 (zh) |
| MX (1) | MX2009001349A (zh) |
| NO (1) | NO20090986L (zh) |
| PE (1) | PE20080538A1 (zh) |
| TW (1) | TW200817409A (zh) |
| WO (1) | WO2008016192A2 (zh) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR066845A1 (es) | 2007-06-05 | 2009-09-16 | Takeda Pharmaceutical | Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer |
| CN101842011A (zh) * | 2007-08-17 | 2010-09-22 | 安克进药物公司 | 作为钾通道调节剂的杂环 |
| US8431608B2 (en) | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
| EP2181987B9 (en) | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer |
| CN101981033B (zh) * | 2008-02-06 | 2015-02-04 | 百时美施贵宝公司 | 用作激酶抑制剂的取代的咪唑并哒嗪化合物 |
| AR070487A1 (es) | 2008-02-28 | 2010-04-07 | Novartis Ag | Derivados de 3- metil- imidazo -( 1,2-b)- piridazina |
| CN101372475B (zh) * | 2008-03-19 | 2012-01-04 | 南京工业大学 | 芳杂环取代的二苯脲类衍生物及其用途 |
| JPWO2009128520A1 (ja) | 2008-04-18 | 2011-08-04 | 塩野義製薬株式会社 | Ｐｉ３ｋ阻害活性を有する複素環化合物 |
| US8445509B2 (en) | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
| WO2010007099A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| BRPI0920707A2 (pt) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| WO2010064611A1 (ja) * | 2008-12-01 | 2010-06-10 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| EP2370428B1 (en) | 2008-12-11 | 2016-08-10 | Respivert Limited | P38 map kinase inhibitors |
| MX2011006425A (es) | 2008-12-24 | 2011-07-20 | Syngenta Ltd | Metodos para la preparacion de fungicidas. |
| EA019647B1 (ru) | 2009-02-10 | 2014-05-30 | Астразенека Аб | ПРОИЗВОДНЫЕ ТРИАЗОЛО[4,3-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EP2563792B1 (en) | 2010-04-28 | 2014-08-27 | Bristol-Myers Squibb Company | Imidazopyridazinyl compounds and their uses for cancer |
| CA2831922C (en) | 2011-04-01 | 2019-12-31 | Genentech, Inc. | Combinations of akt inhibitor compounds and vemurafenib, and methods of use |
| RU2586333C1 (ru) | 2011-12-09 | 2016-06-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные 4-гидрокси-1,2,3,4-тетрагидронафталин-1-ил-мочевины и их применение в лечении, среди прочего, заболеваний дыхательного тракта |
| US9822418B2 (en) | 2013-04-22 | 2017-11-21 | Icahn School Of Medicine At Mount Sinai | Mutations in PDGFRB and NOTCH3 as causes of autosomal dominant infantile myofibromatosis |
| CA2913417A1 (en) | 2013-05-30 | 2014-12-11 | Kala Pharmaceuticals, Inc. | Substituted n-(5-(2-aminoimidaz0[1,2-b]pyridazin-6-yloxy) derivatives a nd pharmaceutical compositions thereof useful for the treatment of diseases associated with abnormal angiogenesis and/or aberrant signaling of a growth factor |
| EP3077393A1 (en) * | 2013-12-06 | 2016-10-12 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| HRP20190840T2 (hr) | 2013-12-13 | 2023-03-17 | Eurochem Agro Gmbh | Mješavina gnojiva koja sadrži inhibitor nitrifikacije |
| WO2016086026A1 (en) * | 2014-11-26 | 2016-06-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of a therapeutic compound and uses thereof |
| JPWO2016093299A1 (ja) * | 2014-12-10 | 2017-09-21 | 千寿製薬株式会社 | 水性液剤 |
| MX386416B (es) | 2016-04-04 | 2025-03-18 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida. |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| HUE063877T2 (hu) | 2016-05-18 | 2024-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása |
| JP2019519582A (ja) | 2016-06-29 | 2019-07-11 | オリオン コーポレーション | ベンゾジオキサン誘導体およびその医薬用途 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| EP3541431B1 (en) | 2016-11-16 | 2024-04-17 | The General Hospital Corporation | Myeloperoxidase imaging agents |
| DE102017201608A1 (de) | 2017-02-01 | 2018-08-02 | Eurochem Agro Gmbh | 3,4-Dimethylpyrazol enthaltende Mischung und ihre Verwendung |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| JP7618237B2 (ja) * | 2019-10-16 | 2025-01-21 | 国立大学法人京都大学 | 運動神経細胞変性阻害剤 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20220389488A1 (en) * | 2021-03-12 | 2022-12-08 | Gt Molecular, Llc | Multiplexed genotyping assays with a single probe using fluorescent amplitude tuning |
| KR20240115979A (ko) | 2021-11-08 | 2024-07-26 | 프로젠토스 테라퓨틱스, 인크. | 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도 |
| CN120187435A (zh) * | 2022-10-27 | 2025-06-20 | 香港科技大学 | 肿瘤的治疗或预防方法 |
| WO2025086243A1 (zh) * | 2023-10-27 | 2025-05-01 | 深圳湾实验室坪山生物医药研发转化中心 | 白细胞受体酪氨酸激酶抑制剂 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989001333A1 (en) | 1987-08-07 | 1989-02-23 | The Australian National University | IMIDAZO[1,2-b]PYRIDAZINES |
| WO1989001478A1 (en) | 1987-08-07 | 1989-02-23 | The Australian National University | ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES |
| GB8719368D0 (en) * | 1987-08-15 | 1987-09-23 | Wellcome Found | Heterocyclic compounds |
| JPH0820584A (ja) | 1994-07-04 | 1996-01-23 | Takeda Chem Ind Ltd | イミダゾール誘導体及びその用途 |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| ATE253051T1 (de) | 1999-01-22 | 2003-11-15 | Kirin Brewery | Chinolinderivate und chinazolinderivate |
| EE05330B1 (et) | 1999-11-05 | 2010-08-16 | Astrazeneca Ab | Kinasoliini derivaadid kui VEGF-i inhibiitorid |
| US6573293B2 (en) | 2000-02-15 | 2003-06-03 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| WO2002032872A1 (fr) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Composes a noyau aromatique azote |
| JP2003137785A (ja) * | 2001-08-23 | 2003-05-14 | Takeda Chem Ind Ltd | Ｊｎｋ活性化阻害剤 |
| BRPI0418328A (pt) | 2003-12-31 | 2007-05-02 | Schering Plough Ltd | controle de parasitas em animais pelo uso de derivados de imidazo [1,2-b]piridazina |
| JP4935357B2 (ja) * | 2004-11-08 | 2012-05-23 | Ｍｓｄ株式会社 | 新規縮環イミダゾール誘導体 |
| US20080167314A1 (en) * | 2004-12-28 | 2008-07-10 | Osamu Uchikawa | Condensed Imidazole Compound And Use Thereof |
| WO2007013673A1 (en) | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| WO2007025090A2 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| US7723336B2 (en) * | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| JPWO2008016131A1 (ja) * | 2006-08-04 | 2009-12-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
-
2007
- 2007-08-03 KR KR1020097004527A patent/KR20090047509A/ko not_active Withdrawn
- 2007-08-03 US US12/064,903 patent/US8044049B2/en active Active
- 2007-08-03 MX MX2009001349A patent/MX2009001349A/es unknown
- 2007-08-03 EP EP07792327.4A patent/EP2049541B1/en active Active
- 2007-08-03 BR BRPI0714665-5A patent/BRPI0714665A2/pt not_active IP Right Cessation
- 2007-08-03 AR ARP070103435A patent/AR062207A1/es unknown
- 2007-08-03 WO PCT/JP2007/065681 patent/WO2008016192A2/en not_active Ceased
- 2007-08-03 JP JP2009522492A patent/JP5238697B2/ja active Active
- 2007-08-03 AU AU2007279595A patent/AU2007279595A1/en not_active Abandoned
- 2007-08-03 PE PE2007001018A patent/PE20080538A1/es not_active Application Discontinuation
- 2007-08-03 CA CA002659971A patent/CA2659971A1/en not_active Abandoned
- 2007-08-03 CL CL200702261A patent/CL2007002261A1/es unknown
- 2007-08-03 TW TW096128518A patent/TW200817409A/zh unknown
-
2008
- 2008-11-03 US US12/263,841 patent/US20100168424A1/en not_active Abandoned
- 2008-11-03 US US12/263,884 patent/US8034812B2/en active Active
- 2008-11-03 US US12/263,949 patent/US8273741B2/en active Active
-
2009
- 2009-01-29 IL IL196799A patent/IL196799A0/en unknown
- 2009-02-09 CR CR10607A patent/CR10607A/es not_active Application Discontinuation
- 2009-02-17 MA MA31647A patent/MA30651B1/fr unknown
- 2009-03-04 NO NO20090986A patent/NO20090986L/no not_active Application Discontinuation
- 2009-03-04 CO CO09022290A patent/CO6150183A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2659971A1 (en) | 2008-02-07 |
| AR062207A1 (es) | 2008-10-22 |
| EP2049541A2 (en) | 2009-04-22 |
| IL196799A0 (en) | 2009-11-18 |
| US8044049B2 (en) | 2011-10-25 |
| CR10607A (es) | 2009-03-12 |
| KR20090047509A (ko) | 2009-05-12 |
| JP5238697B2 (ja) | 2013-07-17 |
| JP2009545583A (ja) | 2009-12-24 |
| AU2007279595A2 (en) | 2009-03-19 |
| US20090306374A1 (en) | 2009-12-10 |
| US20090137595A1 (en) | 2009-05-28 |
| EP2049541B1 (en) | 2015-09-23 |
| US20100168424A1 (en) | 2010-07-01 |
| US20100273788A1 (en) | 2010-10-28 |
| CL2007002261A1 (es) | 2008-05-02 |
| PE20080538A1 (es) | 2008-06-18 |
| MX2009001349A (es) | 2009-04-17 |
| US8273741B2 (en) | 2012-09-25 |
| US8034812B2 (en) | 2011-10-11 |
| CO6150183A2 (es) | 2010-04-20 |
| WO2008016192A3 (en) | 2008-05-08 |
| TW200817409A (en) | 2008-04-16 |
| MA30651B1 (fr) | 2009-08-03 |
| AU2007279595A1 (en) | 2008-02-07 |
| WO2008016192A2 (en) | 2008-02-07 |
| BRPI0714665A2 (pt) | 2012-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20090986L (no) | Sammensmeltet heterosyklisk derivat og anvendelse derav | |
| MX2021006283A (es) | Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos. | |
| NO20081893L (no) | 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft | |
| UA109775C2 (xx) | N-вмісні гетероарильні похідні як інгібітори jak3-кінази | |
| MX378499B (es) | Compuestos antifungicos. | |
| NO20064519L (no) | Karbolinderivater som er anvendbare ved inhibering av angiogenese | |
| NO20082089L (no) | Fosfatidylinositol 3-kinaseinhibitorer og deres anvendelse | |
| NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
| EA201170735A1 (ru) | Производные бензотиазола в качестве средств против рака | |
| BR112018072168A2 (pt) | compostos derivados da pirimidina como inibidores da quinase jak | |
| EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
| TN2009000128A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
| NO20083567L (no) | Hydantoinderivater for behandling av inflammatoriske forstyrrelser | |
| NO20090295L (no) | Substituerte heteroarylderivater | |
| NO20074634L (no) | Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer | |
| CR9830A (es) | Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa | |
| UA107951C2 (xx) | Похідні імідазопіридину як інгібітори jak | |
| TR201905814T4 (tr) | Jak inhibitörü olarak bipirazol tuzu. | |
| NO20083923L (no) | Pyrazolkinoloner er potente parp-inhibitorer | |
| EA201990833A1 (ru) | Соединение пиридина | |
| ATE517107T1 (de) | Pyrrolopyrazinkinaseinhibitoren | |
| EA201691625A1 (ru) | Ароматические гетероциклические соединения как противовоспалительные соединения | |
| NO20092711L (no) | Metoder for anvendelse av cyclopaminanaloger | |
| SMP201000124B (it) | Derivati di chinoline e chinossaline come inibitori di proteina tirosina chinasi | |
| EA201170872A1 (ru) | Ингибиторы протеинкиназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |